Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 27 FEBRUARY 2025

Corporate Transparency Act Reporting Requirements Reinstated

RQC Group
Explore more from RQC Group

In the latest episode of the continuing "on again, off again, on again" courtroom saga, on February 18th the U.S. District Court for the Eastern District of Texas...

United StatesCorporate/Commercial Law
Mark Buckley-Jones
Mark Buckley-Jones

Director

In the latest episode of the continuing "on again, off again, on again" courtroom saga, on February 18th the U.S. District Court for the Eastern District of Texas lifted a previous injunction that had blocked the enforcement of the Corporate Transparency Act ("CTA"), thereby reinstating the requirement for companies to disclose their beneficial owners to the Financial Crimes Enforcement Network ("FinCEN").

FinCEN subsequently issued guidance making clear that beneficial ownership information ("BOI") reporting is now mandatory for reporting companies but extended the BOI Report filing deadlines as follows:

1. Entities registered before January 1, 2024

  • BOI reports must be filed by March 21, 2025

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP